Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China

Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate ApolloBio's new clinical results further highlight the potential of INOVIO's DNA medicine platform to treat diseases caused by...